Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

In essence, the future of AI is inextricably linked to advancements in data management, making it an indispensable enabler of ...

A US clinical-stage biotechnology company has introduced the first bipedal humanoid robot in its AI-driven, fully automated ...

AI-driven drug discovery can analyse millions of chemical compounds in ... Of these drugs, three are undergoing Phase II ...

Around the middle of February, shares of Recursion Pharmaceuticals bounded higher after the company reported phase 2 results ...

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

Recursion is currently generating limited revenue through partnerships with larger pharmaceutical leaders like Merck and ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

The Chinese health care technology sector is in the midst of a transformative phase, fueled by breakthroughs in artificial ...

Two Eradivir employees conduct research on the company's EV25 influenza therapeutic. Eradivir, a clinical stage biotech ...